Transforming growth factor (TGF)-may play an important role in airway remodelling and the fibrogenic effect of TGF-may be mediated through connective tissue growth factor (CTGF) release. We investigated the role of MAPKs and phosphatidylinositol 3-kinase (PI3- 
Introduction
Structural changes of airway smooth muscle cells (ASMC) leading to hyperplasia and hypertrophy with increased release of ECM proteins may play an important role in the pathophysiology of asthma (1, 2) . The mechanisms that mediate these changes in ASMC are not well understood. Transforming growth factor (TGF)-is a polypeptide that is commonly associated with various disorders of inflammation and repair, such as asthma and chronic obstructive airway disease. TGF-is expressed in human ASMC, and increased expression of the isoform, TGF-1, has been demonstrated in ASMC of patients with asthma compared to nonasthmatic airways (3) (4) (5) . A variety of cells, including macrophages, platelets, epithelial cells and ASMC, can produce TGF-and increased levels of TGF-have been detected in bronchial biopsy specimens (6,7) and bronchoalveolar lavage fluid samples (8) from subjects with asthma. TGF-induces proliferation of ASMC (9,10) and enhances the production and release of ECM proteins from airway smooth muscle, and may induce collagen 1 synthesis by an autocrine effect (5) . Therefore, TGF-may be an important mediator of airway remodelling.
Connective tissue growth factor (CTGF), originally identified as a growth factor secreted by endothelial cells (11) promotes fibroblast proliferation, migration, adhesion and ECM production (12). In addition, CTGF exhibits other biological actions in vitro such as vascular smooth muscle migration, angiogenesis and apoptosis (13, 14) . CTGF upregulates collagen I and fibronectin in human lung fibroblasts and vascular smooth muscle cells (13, 15) .
Overproduction of CTGF may therefore be an important pathway leading to fibrosis.
Synergy between CTGF and TGF-1 could also occur through the direct binding of TGF-1 to CTGF, or through enhancement of TGF-1 binding to its receptor by CTGF or by the potentiation of Smad 2/3 phosphorylation induced by TGF-1 (16) . Of particular interest to the current work, CTGF is transcriptionally activated by TGF-and has been shown as a downstream mediator of TGF-mediating its profibrotic activity (12, 17) . A recent study showed that ASMC also expresses CTGF and increased expression of CTGF stimulated by TGF-has been demonstrated in ASMC cultured from asthmatic subjects (18) . Therefore, CTGF induction by TGF-may be an important mechanism of airway remodelling in asthma.
The mechanism mediating increased CTGF expression by TGF-in ASMC remains unknown. MAPKs are a family of protein kinases that phosphorylate specific serines and threonines of target protein substrates to regulate cellular activities (19) In order to understand the intracellular mechanisms of CTGF activation by TGF-, we investigated the role of ERK, JNK, p38 MAPKs and PI3-K in ASMC. We also examined whether cytokines involved in allergen inflammation, IL-4 and IL-13, and pro-inflammation cytokines, IL-1 and TNF-, can interfere with CTGF production induced by TGF-, and whether these cytokines could modulate TGF--induced Smad signaling.
Materials and Methods

Materials
Recombinant human TGF-1, IL-4, IL-13, IL-1 and TNF-were purchased from R&D Systems (Abingdon, UK). Rabbit polyclonal CTGF antibody (CTGF-ab6992) was from Abcam Ltd (Cambridge, UK). Primers for CTGF and GAPDH were obtained from Sigma Genosys (Pampisford, Cambridgeshire, UK). PD98059, SB203580 and wortmannin were purchased from Calbiochem (Nottingham, UK). SP600125 was a kind gift from Celgene Inc.
(San Diego, CA, USA). Antibodies for phospho-specific ERK1/2 (p-ERK1/2), ERK1/2, phospho-Smad2/3 (p-Smad2/3) (Ser465/467), and the anti-rabbit horseradish peroxidase (HRP)-conjugated IgG were obtained from Cell signaling Technology Inc (Hertfordshire, UK).
Anti-Smad2/3 antibody was from Upstate (Milton Keynes, UK). Enhanced chemiluminescence (ECL) reagent was from Amersham International (Amersham, Bucks, UK). Tissue culture media and reagents were purchased form Sigma or Gibco-BRL (Paisley, Strathclyde, UK).
Cell culture and treatment
ASMC were isolated from fresh lobar or main bronchus obtained from lung resection donors by treatment with collagenase, and cultured in DMEM supplemented with 10% heatinactivated FCS as described previously (24). ASMC characteristics were identified by light microscopy with typical 'hill and valley' appearance and by positive immunostaining of smooth muscle (SM) -actin, SM myosin heavy chain, calponin and SM-22. The cells were maintained in T175 or T75 culture flasks at 37 0 C in a humidified atmosphere of 5% CO 2 . For these experiments, ASMC were studied from passages three to six.
Cells were trypsinized and subcultured in 6-well plates for total protein and RNA extractions. After reaching confluence in 10% FCS DMEM, cells were incubated for 2-3 days in serum-free medium containing 0.5% BSA before treatment. Cells were treated with TGFor the appropriate test reagents in serum-free medium containing 0.5% BSA. Control cultures were incubated in the medium-containing vehicle alone.
Western Blotting
Total cell protein was extracted on ice with lysis buffer (1% Igepal CA-630, 0.5% sodium deoxycholate, 0.1% SDS in PBS pH 7.4) in the presence of freshly added protease inhibitors including 1 mM phenylmethylsulphonyl fluoride, 5 µg/ml aprotinin, 1 mM Na 3 VO 4 and 5 µg/ml leupeptin. Protein concentration was determined using the Bradford method with a BioRad Protein Assay Reagent. Protein extract (30 µg/lane) was fractionated by SDS-PAGE on a 10% tris-glycine precast gel (Invitrogen), followed by transferring to a nitrocellulose membrane (Amersham). The membrane was incubated overnight at 4 0 C with an antibody for CTGF (0.5 µg/ml), or p-ERK1/2 (1:1000), ERK1/2 (1:1000), P-Smad2/3
(1:1000) or Smad2/3 (2 µg/ml). The next day, the membrane was incubated for 1 h with a HRP-conjugated secondary antibody raised against rabbit IgG (1:2000) at room temperature.
Antibody-bound proteins were visualised by ECL. The membranes were stripped and then reprobed with a mouse anti-GAPDH monoclonal antibody (1:5000, Biogenesis, Poole, UK) in order to control for the loading. Relevant band intensities were quantified by scanning densitometric analysis using software from Ultra-Violet Products (UVP, Cambridge, UK).
Densitometric data were normalized for GAPDH values.
Real-time RT-PCR
Total RNA was isolated from ASMC by using the RNeasy Mini Kit (Qiagen, West Sussex, UK) or TRIzol (Invitrogen) according to the manufacturer's instructions. cDNA was generated by RT using random hexamers and an AMV reverse transcriptase (Promega). The cDNA (42 ng/reaction) was used as a template in the subsequent PCR analyses. 
Immunocytochemistry and immunofluorescence
Immunocytochemistry was performed to detect the presence of CTGF in ASMC grown on chamber slides in the presence or absence of TGF-. The cells were fixed in 3.7%
formaldehyde in PBS for 10 min followed by cold methanol for 4 min and cold acetone for 1 min. Immunostaining was carried out in accordance with the directions supplied by the Vectastain Kit (Vector Laboratories). CTGF was detected using the rabbit polyclonal CTGF antibody (5 µg/ml, 1 h). Sections were incubated with the avidin/biotinylated alkaline phosphatase complex and then Sigma Fast Red chromogenic solution. Sections were counterstained with 2% haematoxylin.
Immunofluorescence was carried out to detect translocation of p-Smad2/3 and Smad4
following stimulation of TGF-. The cells were fixed with 4% paraformaldehyde for 15 min at 
Data analysis
Data were analysed by ANOVA using the software program, Statview (Abacus Concept, Inc., Berkeley, CA, USA). Results are expressed as mean ± SEM and representative of at least three separate experiments. P<0.05 was used to determine the statistical significance of the data.
Results
TGF-1 induces CTGF mRNA expression in ASMC
ASMC were treated with TGF-1 (0.3-10 ng/ml) in serum-free medium at different time-points (1-24 h). Real-time RT-PCR showed that unstimulated cells expressed baseline levels of CTGF mRNA and that TGF-1 induced a time-dependent increase in CTGF mRNA expression (Fig. 1A) . The expression of CTGF mRNA was almost doubled following 1 h treatment with 10 ng/ml TGF-1, increased 7-fold at 3 h and the maximal effect was seen at 24 h. TGF-1-stimulated expression of CTGF mRNA was sustained after 72 h treatment (data not shown). The effect of TGF-1 on CTGF mRNA was dose-dependent over the range of 0.3 to 10 ng/ml following 24 h treatments (Fig. 1B) . TGF-1 at 1 ng/ml increased CTGF transcript by 6-fold and maximal stimulation was seen at 10 ng/ml by 14-fold compared with unstimulated controls. This concentration was chosen for subsequent experiments.
TGF-1 induces CTGF protein expression of ASMC
ASMC were incubated in 6-well plates in the presence or absence of TGF-1 (0.3-10 ng/ml) for 3-48 h and protein expression of CTGF was analysed by Western blot. There was a time-dependent increase in the expression of CTGF protein in ASMC treated with TGF-1 (10 ng/ml) for 3-48 h ( Fig. 2A and C ). An ~2-fold increase in CTGF level was observed following 6 h treatment with TGF-1, with a 9-fold increase following 24 h, reaching maximal levels following 48 h (~12-fold). Similar to the effects on CTGF mRNA, TGF-1 also stimulated a dose-dependent increase in the protein expression of CTGF in ASMC treated for 48 h ( Fig. 2B and D) . Immunostaining showed increased expression of CTGF in ASMC following 24 h treatment with 10 ng/ml TGF-1 and was sustained up to 7 days of treatment (data not shown).
Role of MAPKs and PI3-K in CTGF induction by TGF-1
Cells were pre-incubated with specific blockers (PD98059 for ERK, SP600125 for JNK, SB203580 for p38 MAPK, and wortmannin for PI3-K) for 30 min and then co-treated with 10 ng/ml TGF-1 for 24 h for analysis of mRNA expression or for 48 h for protein expression. Treatment of ASMC with PD98059 (10-50 µM) inhibited TGF-1-induced expression of CTGF protein ( Fig. 3A and B) and mRNA ( Fig. 3C ) in a dose-dependent manner. SP600125 induced a similar inhibition in CTGF protein production ( Fig. 4A and B) and mRNA expression (Fig. 4C) by TGF-1. SB203580 (1 µM) and wortmannin (100 nM) had no effect on TGF-1-stimulated protein expression of CTGF (Fig. 4D ). The inhibitors, PD98059, SP600125, SB203580 or wortmannin, alone at the used concentrations, had no effect on CTGF expression, and also did not affect cell viability (data not shown).
Effects of ERK and JNK inhibitors on TGF--induced Smad signalling
TGF-1 induced a time-and concentration-dependent activation of Smad2/3 in ASMC (Fig. 5) . Phosphorylation of Smad2/3 by TGF-was observed following 10 min treatment (data not shown) and was sustained for up to 48h ( Fig. 5A and B) . The maximal activity was seen at 10 ng/ml of TGF-( Fig. 5C and D) . Immunofluorescence showed the translocation of p-Smad2/3 and Smad4 from cytosol to nucleus after TGF-stimulation and there was increasing signal in the nucleus and corresponding decreases in the cytosol for Smad4 (data not shown). Pretreatment with PD98059 (10-50 µM), a selective blocker for ERK, led to inhibition of the TGF--induced p-Smad2/3 in a concentration-dependent manner (Fig. 6A TGF-1 at 1 ng/ml increased CTGF transcript by 6-fold and maximal stimulation was seen at 10 ng/ml by 14-fold compared with unstimulated controls. This concentration was chosen for subsequent experiments.and B). A similar inhibition was achieved when cells were pretreated with JNK blocker, SP600125 (Fig. 6B) . In contrast, SB203580 (1 µM) and wortmannin (100 nM) did not affect Smad2/3 phosphorylation (data not shown).
Effect of IL-4 and IL-13 on TGF-1-induced CTGF expression, and ERK and Smad activation
Following 48 h of stimulation with 10 ng/ml of IL-4 or IL-13, basal CTGF protein levels
were not changed as assessed by Western blot ( (Fig. 8A ) and IL-13 had a similar effect (data not shown). The basal and TGF-1-induced ERK phosphorylation was blocked when cells were pretreated with ERK blocker PD98059 at 50 µM concentration (Fig. 8A) . IL-4 and IL-13 also inhibited TGF--induced activation of Smad2/3 at a concentration-dependent manner ( Fig. 8B and C) .
Interaction of TGF-1 with TNF-and IL-1 on CTGF expression and Smad activation
To investigate the interaction between TGF-1 and the pro-inflammatory cytokines, TNF-and IL-1 , on CTGF expression, cells were incubated with TGF-1 (10 ng/ml) in the presence of TNF-(20 ng/ml) or IL-1 (10 ng/ml). Significant suppression of basal and TGF-1-induced expression of CTGF mRNA was observed when cells were incubated with TNF- (Fig. 9A) . IL-1 modestly decreased the basal and TGF-1-induced mRNA expression of CTGF. TNF-slightly reduced CTGF protein production by TGF-but IL-1 had no prominent effect as determined by Western blot (Fig. 9B) . There was no effect on CTGF 
